आईएसएसएन: 2157-7013
Yasuo Iwadate
Glioblastoma (GBM) is the most devastating type of human cancers with a median survival time ranging from 12-18 months following maximal therapies [1]. Glioma is classified into four malignancy grades according to histological features; the low-grade tumors including WHO Grade I (localized gliomas) and WHO Grade II (diffuse astrocytoma or oligodendrogliomas), and the high-grade tumors including WHO Grades III (anaplastic gliomas) and WHO Grade IV (GBM).